President Trump’s recent decision to name Kyle Diamantas acting FDA commissioner following Marty Makary’s May 2026 resignation has positioned Diamantas as the frontrunner in trader assessments for a permanent appointment. Diamantas, who previously led the agency’s Human Foods Program and served as a senior counselor to HHS Secretary Robert F. Kennedy Jr., has advanced administration priorities on food additives and safety standards aligned with the Make America Healthy Again agenda. The administration has stated that a formal search for a confirmed commissioner is underway with Senate confirmation required, which introduces standard procedural timelines and potential delays. Other named candidates, including former commissioner Stephen Hahn and Brett Giroir, register lower probabilities amid limited recent signals of endorsement, while the option of no announcement by year-end reflects ongoing uncertainty over the pace of the selection process.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoKyle Diamantas 53%
No announcement by December 31 11.6%
Stephen Hahn 4%
Sara Brenner 3.3%
NUOVO
NUOVO
31 dic 2026
Kyle Diamantas
53%
Stephen Hahn
4%
Brett Giroir
3%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
12%
Kyle Diamantas 53%
No announcement by December 31 11.6%
Stephen Hahn 4%
Sara Brenner 3.3%
NUOVO
NUOVO
31 dic 2026
Kyle Diamantas
$1,525 Vol.
53%
Stephen Hahn
$976 Vol.
4%
Brett Giroir
$1,510 Vol.
3%
Grace Graham
$1,893 Vol.
3%
Sara Brenner
$849 Vol.
3%
No announcement by December 31
$533 Vol.
12%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent decision to name Kyle Diamantas acting FDA commissioner following Marty Makary’s May 2026 resignation has positioned Diamantas as the frontrunner in trader assessments for a permanent appointment. Diamantas, who previously led the agency’s Human Foods Program and served as a senior counselor to HHS Secretary Robert F. Kennedy Jr., has advanced administration priorities on food additives and safety standards aligned with the Make America Healthy Again agenda. The administration has stated that a formal search for a confirmed commissioner is underway with Senate confirmation required, which introduces standard procedural timelines and potential delays. Other named candidates, including former commissioner Stephen Hahn and Brett Giroir, register lower probabilities amid limited recent signals of endorsement, while the option of no announcement by year-end reflects ongoing uncertainty over the pace of the selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Mercato aperto: May 12, 2026, 7:59 PM ET
Volume
$7,286Data di fine
31 dic 2026Mercato aperto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent decision to name Kyle Diamantas acting FDA commissioner following Marty Makary’s May 2026 resignation has positioned Diamantas as the frontrunner in trader assessments for a permanent appointment. Diamantas, who previously led the agency’s Human Foods Program and served as a senior counselor to HHS Secretary Robert F. Kennedy Jr., has advanced administration priorities on food additives and safety standards aligned with the Make America Healthy Again agenda. The administration has stated that a formal search for a confirmed commissioner is underway with Senate confirmation required, which introduces standard procedural timelines and potential delays. Other named candidates, including former commissioner Stephen Hahn and Brett Giroir, register lower probabilities amid limited recent signals of endorsement, while the option of no announcement by year-end reflects ongoing uncertainty over the pace of the selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$7,286Data di fine
31 dic 2026Mercato aperto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...President Trump’s recent decision to name Kyle Diamantas acting FDA commissioner following Marty Makary’s May 2026 resignation has positioned Diamantas as the frontrunner in trader assessments for a permanent appointment. Diamantas, who previously led the agency’s Human Foods Program and served as a senior counselor to HHS Secretary Robert F. Kennedy Jr., has advanced administration priorities on food additives and safety standards aligned with the Make America Healthy Again agenda. The administration has stated that a formal search for a confirmed commissioner is underway with Senate confirmation required, which introduces standard procedural timelines and potential delays. Other named candidates, including former commissioner Stephen Hahn and Brett Giroir, register lower probabilities amid limited recent signals of endorsement, while the option of no announcement by year-end reflects ongoing uncertainty over the pace of the selection process.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti